Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$2.57
+6.2%
$3.53
$2.37
$7.63
$325.51M1.42741,030 shs1.53 million shs
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$5.96
+4.9%
$5.81
$3.91
$13.99
$410.11M1.58818,451 shs1.45 million shs
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
$20.44
+7.2%
$17.17
$8.62
$21.22
$197.80M0.3872,422 shs399,768 shs
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$1.03
+11.8%
$1.12
$0.92
$2.65
$391.22M1.82.14 million shs2.15 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
0.00%-10.04%-35.81%-52.83%-59.40%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
0.00%-6.89%-10.83%-4.70%-49.10%
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
0.00%+5.83%+1.38%+22.87%+102.01%
Standard BioTools Inc. stock logo
LAB
Standard BioTools
0.00%-12.23%-20.55%-27.15%-63.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.0818 of 5 stars
3.12.00.00.03.21.70.6
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
2.1052 of 5 stars
3.52.00.00.03.41.70.0
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
1.4315 of 5 stars
0.03.00.00.02.04.20.6
Standard BioTools Inc. stock logo
LAB
Standard BioTools
2.0754 of 5 stars
3.30.00.00.02.34.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.25
Hold$5.25104.28% Upside
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
3.00
Buy$25.38325.76% Upside
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
0.00
N/AN/AN/A
Standard BioTools Inc. stock logo
LAB
Standard BioTools
2.50
Moderate Buy$2.50142.72% Upside

Current Analyst Ratings Breakdown

Latest FEIM, CTKB, LAB, and EYPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/12/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$3.50 ➝ $3.00
5/9/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$4.00
5/8/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$33.00 ➝ $27.00
3/19/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.00 ➝ $6.00
3/6/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
3/6/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
3/4/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.50 ➝ $8.00
2/27/2025
Standard BioTools Inc. stock logo
LAB
Standard BioTools
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Sector Weight
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$197.05M1.65$0.01 per share206.16$2.90 per share0.89
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$56.04M7.32N/AN/A$5.66 per share1.05
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
$65.40M3.02$1.02 per share20.00$4.20 per share4.87
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$169.69M2.31N/AN/A($1.85) per share-0.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$12.15M-$0.09N/AN/A-5.05%-2.58%-2.05%8/5/2025 (Estimated)
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%8/6/2025 (Estimated)
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
$5.59M$2.4124.93N/A13.02%21.49%9.71%7/21/2025 (Estimated)
Standard BioTools Inc. stock logo
LAB
Standard BioTools
-$74.66M-$0.35N/AN/AN/A-79.92%-27.05%-15.52%7/30/2025 (Estimated)

Latest FEIM, CTKB, LAB, and EYPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$0.04-$0.09-$0.05-$0.09$43.18 million$41.46 million
5/7/2025Q1 2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
3/13/2025Q3 2025
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
N/A$1.60N/A$1.60N/A$18.93 million
3/5/2025Q4 2024
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.54-$0.64-$0.10-$0.64$11.02 million$11.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/AN/AN/AN/AN/A
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
N/AN/AN/AN/AN/A
Standard BioTools Inc. stock logo
LAB
Standard BioTools
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
6.21
5.47
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/A
5.50
5.45
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
N/A
1.79
0.93
Standard BioTools Inc. stock logo
LAB
Standard BioTools
N/A
3.76
3.41

Institutional Ownership

CompanyInstitutional Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
99.41%
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
58.60%
Standard BioTools Inc. stock logo
LAB
Standard BioTools
53.74%

Insider Ownership

CompanyInsider Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
9.60%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
4.74%
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
26.10%
Standard BioTools Inc. stock logo
LAB
Standard BioTools
23.16%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
500126.66 million116.45 millionOptionable
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
12068.81 million65.02 millionOptionable
Frequency Electronics, Inc. stock logo
FEIM
Frequency Electronics
2009.68 million7.10 millionNot Optionable
Standard BioTools Inc. stock logo
LAB
Standard BioTools
620379.82 million174.59 millionOptionable

Recent News About These Companies

Standard BioTools announces new product innovations at AACR 2025
Q4 2024 Standard BioTools Inc Earnings Call
Standard BioTools downgraded to Sector Weight from Overweight at KeyBanc
Keybanc Downgrades Standard BioTools (LAB)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cytek Biosciences stock logo

Cytek Biosciences NASDAQ:CTKB

$2.57 +0.15 (+6.20%)
Closing price 04:00 PM Eastern
Extended Trading
$2.57 0.00 (0.00%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

EyePoint Pharmaceuticals stock logo

EyePoint Pharmaceuticals NASDAQ:EYPT

$5.96 +0.28 (+4.93%)
Closing price 04:00 PM Eastern
Extended Trading
$5.96 +0.00 (+0.02%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Frequency Electronics stock logo

Frequency Electronics NASDAQ:FEIM

$20.44 +1.37 (+7.18%)
Closing price 04:00 PM Eastern
Extended Trading
$20.23 -0.22 (-1.05%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Frequency Electronics, Inc., together with its subsidiaries, engages in designing, development, and manufacturing of precision time and frequency control products and components for microwave integrated circuit applications. It operates through two segments, FEI-NY and FEI-Zyfer. The FEI-NY segment offers precision time and frequency control products for communication satellites, terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military; and provides design and technical support for satellite business. FEI-Zyfer segment offers global positioning system technologies to systems and subsystems for secure communications, both government and commercial, and other locator applications; and engages in sale and support of wireline telecommunications products, including US5G. It markets its products directly and through independent sales representative organizations located in the United States, Europe, and Asia. Frequency Electronics, Inc. was founded in 1961 and is headquartered in Mitchel Field, New York.

Standard BioTools stock logo

Standard BioTools NASDAQ:LAB

$1.03 +0.11 (+11.76%)
Closing price 04:00 PM Eastern
Extended Trading
$1.02 -0.01 (-0.49%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.